BRIUMVITM (ublituximab-xiiy) IS NOW APPROVED. PRESCRIBING INFORMATION

FIERCELY FOCUSED
ON SCIENCE

OUR PIPELINE

REGIMEN Disease Preclinical Phase 1 Phase 2 Phase 3 Registration Status Learn More
Ublituximab monotherapy: glycoengineered anti-CD20 mAb Relapsing MS
ULTIMATE I and II
NOW APPROVED
12/28/2022
learnmore
TG-1801: anti-CD47/CD19 bispecific mAb B-cell disorders
learnmore
TG-1701: BTK inhibitor B-cell disorders
learnmore

The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.

Single Agent

REGIMEN Preclinical Phase 1 Phase 2 Phase 3

Ublituximab monotherapy: glycoengineered anti-CD20 mAb

DiseaseRelapsing MS

Learn More learnmore

ULTIMATE I and II

NOW APPROVED 12/28/2022

EARLY PIPELINE

REGIMEN Preclinical Phase 1 Phase 2 Phase 3
TG-1801: anti-CD47/CD19 bispecific mAb

DiseaseB-cell disorders

Learn More learnmore

TG-1701: BTK inhibitor

DiseaseB-cell disorders

Learn More learnmore

The safety and efficacy of our investigational compounds and investigational uses of approved products have not been established. These products and uses have not been approved by the US Food and Drug Administration or other health authorities.